Abstract:AIMS/HYPOTHESIS:Notwithstanding the irreversible beta cell failure seen in type 1 diabetes, some individuals may experience a special phase named 'partial remission' or 'the honeymoon period', in which there is a transient recovery of beta cell function. Importantly, this stage of partial remission shows spontaneous immune downregulation, although the exact mechanisms are unclear. Intracellular energy metabolism is crucial for the differentiation and function of T cells, and provides promising targets for immunometabolic intervention strategies, but its role during partial remission is unknown. In this study, we aim to investigate the association between T cell intracellular glucose and fatty acid metabolism and the partial remission phase.METHODS:This is a cross-sectional study with a follow-up component. Intracellular uptake of glucose and fatty acids by T cells was detected in participants with either new-onset type 1 diabetes or type 1 diabetes that was already in partial remission, and compared with heathy individuals and participants with type 2 diabetes. Subsequently, the participants with new-onset type 1 diabetes were followed up to determine whether they experienced a partial remission (remitters) or not (non-remitters). The trajectory of changes in T cell glucose metabolism was observed in remitters and non-remitters. Expression of programmed cell death-1 (PD-1) was also analysed to investigate possible mechanisms driving altered glucose metabolism. Partial remission was defined when patients had convalescent fasting or 2 h postprandial C-peptide >300 pmol/l after insulin treatment.RESULTS:Compared with participants with new-onset type 1 diabetes, intracellular glucose uptake by T cells decreased significantly in individuals with partial remission. The trajectory of these changes during follow-up showed that intracelluar glucose uptake in T cells fluctuated during different disease stages, with a decreased uptake during partial remission that rebounded after remission. This dynamic in T cell glucose uptake was only detected in remitters and not in non-remitters. Further analysis demonstrated that changes of intracellular glucose uptake were found in subsets of CD4+ and CD8+ T cells, including Th17, Th1, CD8+ naive T cells (Tn) and CD8+ terminally differentiated effector memory T cells (Temra). Moreover, glucose uptake in CD8+ T cells was negatively related to PD-1 expression. The intracellular metabolism of fatty acids was not found to be different between new-onset participants and those in partial remission.CONCLUSIONS/INTERPRETATION:Intracellular glucose uptake in T cells was specifically decreased during partial remission in type 1 diabetes and may be related to PD-1 upregulation, which may be involved in the down-modulation of immune responses during partial remission. This study suggests that altered immune metabolism could be a target for interventions at the point of diagnosis of type 1 diabetes.

Three‐phasic Pattern of C‐peptide Decline in Type 1 Diabetes Patients with Partial Remission

Factors Associated With Decline Of C-Peptide In A Cohort Of Young Children Diagnosed With Type 1 Diabetes

Frequency, Clinical Characteristics and Determinants of Partial Remission in Type 1 Diabetes: Different Patterns in Children and Adults.

Factors Associated With the Decline of C-Peptide in a Cohort of Young Children Diagnosed With Type 1 Diabetes.

Preserved C-peptide is common and associated with higher time in range in Chinese type 1 diabetes

Approaches to Measuring Beta Cell Reserve and Defining Partial Clinical Remission in Paediatric Type 1 Diabetes

Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration

Recovery of Intracellular Glucose Uptake in T Cells During Partial Remission of Type 1 Diabetes

Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes

Preserved C-peptide Secretion is Associated with Higher Time in Range (TIR) on Intermittently Scanned Continuous Glucose Monitoring in Chinese Adults with Type 1 Diabetes

Residual Β-Cell Function after 10 Years of Autoimmune Type 1 Diabetes: Prevalence, Possible Determinants, and Implications for Metabolism

Using Glycated Albumin and Stimulated C-Peptide to Define Partial Remission in Type 1 Diabetes

Decline Pattern of Beta-cell Function in Adult-onset Latent Autoimmune Diabetes: an 8-year Prospective Study

PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells is Restored in the Partial Remission Phase in Type 1 Diabetes

Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications

Variation of C Peptide Decay Rate in Diabetic Patients with Positive Glutamic Acid Decarboxylase Antibody: Better Discrimination with Initial Fasting C Peptide

Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function

1484-P: CD57+CD8+T Cells Exhibit Distinct Features in T1D Patients with Partial Remission Phase

C-Peptide-Positive, Autoantibody-Negative Type 1 Diabetes Mellitus

1175-P: Circulating CD4+/CD8+ PD-1+ T Cells Are Increased During the Partial Remission Phase in Patients with Type 1 Diabetes

[The clinical utility of C-peptide measurement in diabetology].